Brii BioSciences CEO and leadership

Dr. Hong co-founded Brii Bio in 2018 and has served as Chief Executive Officer since the company’s inception. Prior to starting Brii Bio, Dr. Hong was Senior Vice President and Head of GlaxoSmithKline's (GSK) Infectious Diseases Therapy Area Unit. He was widely credited as the key architect of GSK's comeback and success in HIV and Infectious Diseases medicine discovery and development. Under his leadership, ViiV Healthcare’s (a joint venture between GSK, Pfizer, and Shionogi) HIV business was revitalized with the approval of Tivicay and Triumeq. Dr. Hong was the champion of GSK's effort in long-acting HIV treatment and prevention therapies resulting in the first approval of Cabenuva.

Dr. Hong is a public health advocate who has helped establish multiple public-private partnerships with the U.S./E.U. governments (DTRA, BARDA, NIH & IMI) and philanthropic organizations (Gates Foundation & Wellcome Trust). He helped to create GSK's Institute for Infectious Diseases and Public Health in Beijing, China. Dr. Hong started Ardea Biosciences (later acquired by AstraZeneca). He also held leadership positions at Valeant Pharmaceuticals and Schering-Plough Research Institute (now Merck). Dr. Hong has more than 25 years of experience in drug discovery and development and has brought more than 40 compounds into development, including many that have been approved and launched. He has served as a board member of Anacor Pharmaceuticals (acquired by Pfizer) and ViiV Healthcare, and also chaired the board of Qura Therapeutics.

Jim Klein is interim Chief Financial Officer with responsibility for finance, treasury, and general administration. Mr. Klein has over 30 years of senior financial leadership experience in the pharmaceutical, biotech, and medical device industries. He has raised over $400 million as a Chief Financial Officer of various life science companies, including two successful initial public offerings. Mr. Klein specializes in managing growth to entrepreneurial companies, providing executive financial management, long-range strategic planning, financial reporting, cash and treasury management, and operational management. He is well-versed at working with boards of directors, including compensation and audit committees. Mr. Klein graduated from the University of Mississippi with a degree in accounting and is a Certified Public Accountant. Mr. Klein has also attended executive management programs at the London Business School; the Fuqua School of Business at Duke University; and the Kenan-Flagler Business School at The University of North Carolina.

Li Yan, M.D., Ph.D., is Chief Medical Officer and has overall responsibility for clinical development, regulatory affairs, medical affairs, drug safety, and other related functions. He is accountable for developing and driving execution of clinical development programs and registrations.

Prior to joining the company, Dr. Yan was Vice President and Head Unit Physician of GSK Oncology, where he oversaw global development of oncology assets focusing on immunotherapy, cancer epigenetics, and cell therapy. Prior to his tenure at GSK, he was Executive Director at Merck responsible for clinical development of oncology, respiratory and immunology, infectious diseases, and vaccines in emerging markets.

Dr. Yan started his industry career with Centocor, a Johnson & Johnson company, leading both discovery and clinical development of anti-cancer biologics. He has published over 80 manuscripts and book chapters.

Dr. Yan received his medical degree from the Medical College of Peking University and a Ph.D. from the University of Kansas Medical Center. He completed his post-graduate training at Beijing Cancer Hospital, Peking University, and Boston Children’s Hospital (Harvard Medical School). He is also an alumnus of the Harvard Business School enterprise executive program. Dr. Yan holds adjunct professorships at Peking University and Yonsei University, and is Managing Director of the US Chinese Anti-Cancer Association.

Ankang Li are a Chief Financial & Strategy Officer at Brii Biosciences.

Ms. Neuendorff brings more than 20 years of experience as a transformational HR leader with a passion for harnessing human capital as a key driver of business.

Before joining Brii Bio, Ms. Neuendorff served as the Senior Vice President, Human Resources at WeDriveU, a division of the premier transportation firm National Express LLC, where she led HR strategy, recruiting and talent management, acting as a trusted advisor to senior leaders and operational talent alike. Prior to her time at WeDriveU, Ms. Neuendorff served as Vice President, Global Human Resources at Nexant for 14 years, where she managed operational functions for the organization to create a unified, value-based culture and brand globally. Throughout her career, she has converted business vision into HR initiatives that improved performance, profitability, growth, and employee engagement on a global scale.

Ms. Neuendorff holds a Bachelor of Arts degree in Psychology from the University of San Francisco. She is also certified as a Senior Professional in Human Resources (SPHR, SHRM-SCP), a Global Professional in Human Resources (GPHR), and a California Professional in Human Resources (PHR-CA).

Dr. Hong co-founded Brii Bio in 2018 and has served as Chief Executive Officer since the company’s inception. Prior to starting Brii Bio, Dr. Hong was Senior Vice President and Head of GlaxoSmithKline's (GSK) Infectious Diseases Therapy Area Unit. He was widely credited as the key architect of GSK's comeback and success in HIV and Infectious Diseases medicine discovery and development. Under his leadership, ViiV Healthcare’s (a joint venture between GSK, Pfizer, and Shionogi) HIV business was revitalized with the approval of Tivicay and Triumeq. Dr. Hong was the champion of GSK's effort in long-acting HIV treatment and prevention therapies resulting in the first approval of Cabenuva.

Dr. Hong is a public health advocate who has helped establish multiple public-private partnerships with the U.S./E.U. governments (DTRA, BARDA, NIH & IMI) and philanthropic organizations (Gates Foundation & Wellcome Trust). He helped to create GSK's Institute for Infectious Diseases and Public Health in Beijing, China. Dr. Hong started Ardea Biosciences (later acquired by AstraZeneca). He also held leadership positions at Valeant Pharmaceuticals and Schering-Plough Research Institute (now Merck). Dr. Hong has more than 25 years of experience in drug discovery and development and has brought more than 40 compounds into development, including many that have been approved and launched. He has served as a board member of Anacor Pharmaceuticals (acquired by Pfizer) and ViiV Healthcare, and also chaired the board of Qura Therapeutics.

Dr. Hong co-founded Brii Bio in 2018 and has served as Chief Executive Officer since the company’s inception. Prior to starting Brii Bio, Dr. Hong was Senior Vice President and Head of GlaxoSmithKline's (GSK) Infectious Diseases Therapy Area Unit. He was widely credited as the key architect of GSK's comeback and success in HIV and Infectious Diseases medicine discovery and development. Under his leadership, ViiV Healthcare’s (a joint venture between GSK, Pfizer, and Shionogi) HIV business was revitalized with the approval of Tivicay and Triumeq. Dr. Hong was the champion of GSK's effort in long-acting HIV treatment and prevention therapies resulting in the first approval of Cabenuva.

Dr. Hong is a public health advocate who has helped establish multiple public-private partnerships with the U.S./E.U. governments (DTRA, BARDA, NIH & IMI) and philanthropic organizations (Gates Foundation & Wellcome Trust). He helped to create GSK's Institute for Infectious Diseases and Public Health in Beijing, China. Dr. Hong started Ardea Biosciences (later acquired by AstraZeneca). He also held leadership positions at Valeant Pharmaceuticals and Schering-Plough Research Institute (now Merck). Dr. Hong has more than 25 years of experience in drug discovery and development and has brought more than 40 compounds into development, including many that have been approved and launched. He has served as a board member of Anacor Pharmaceuticals (acquired by Pfizer) and ViiV Healthcare, and also chaired the board of Qura Therapeutics.